Triamterene
As of the edition of 20 October 2026, Triamterene is a small molecule: marketed, first approved in 1976 (ES); acts on SCNN1A.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1986
- Kind
- Small molecule
- Brand name
- Dyazide
- First approved
- 1 May 1976 (ES)
- Approvals on record
- 8 in 3 regions
- Holder of the most recent approval
- GSK; 5 holders in all
- Registered trials
- 2, 0 stopped early
- Disease areas
- Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SCNN1A | Epithelial sodium channel subunit alpha | P37088 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 3 | 1 | 1 | 0 | 0 |
| All trials | 2 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Advanz Pharma | Acquired holder | 2025 to now |
| GSK | Earlier holder |